Head-to-head evidence
Ofatumumab vs Ublituximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
Ofatumumab
Marketed by Novartis and partners
NCT02792231 · Phase 3 · completed
This was a large, randomized, quadruple-blind, active-controlled trial of 955 participants, comparing ofatumumab with teriflunomide. The prespecified primary clinical endpoint, annualized confirmed relapse rate, was significantly better with ofatumumab (p<0.001), supporting a strong evidence grade despite mixed findings for some secondary measures.
Next expected readout: April 2027 · NCT05090371 (registry estimate)
Ublituximab
Marketed by TG THERAPEUTICS, INC.
NCT03277261 · Phase 3 · completed
This was a randomized, quadruple-masked, active-controlled trial of 549 participants, with ublituximab and teriflunomide administered alongside matching placebos. The primary clinical endpoint was met: ublituximab produced a significantly lower annualized relapse rate than teriflunomide through 96 weeks (p<0.0001).
Next expected readout: October 2026 · NCT07211633 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ofatumumab's landscape · Ublituximab's landscape